PEDIATRICS Vol. 98 No. 6 December 1996, pp. 1127-1131
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abrahamsen, T. G.
Right arrow Articles by Bustnes, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abrahamsen, T. G.
Right arrow Articles by Bustnes, A.

Home Therapy With Subcutaneous Immunoglobulin Infusions in Children With Congenital Immunodeficiencies

Tore G. Abrahamsen MD, PhD1, Heidi Sandersen PN2, and Alfhild Bustnes PN2

1 The Departments of Pediatrics and Pediatric Research, National Hospital, Oslo, Norway.
2 The Department of Pediatric Research, National Hospital, Oslo, Norway.

Objectives. Patients with congenital, humoral immunodeficiencies are usually treated with intravenous immunoglobulin infusions. Subcutaneous infusions have emerged as an alternative treatment modality also in children. Our institution has run a subcutaneous infusion home therapy program for 6 years, and the purpose of this report is to describe our experience with this regimen.

Methods. The subcutaneous therapy of eight patients with immunodeficiency (three with agammaglobulinemia, one with common variable immunodeficiency, one with severe combined immunodeficiency and bone marrow transplantation, and three with hyper-immunoglobulin M syndrome) was evaluated by chart review and a questionnaire answered by all the families. The infusions were given for at least 3 hours each week by a small syringe driver at home after the family had attended an intensive educational course at the hospital.

Results. The children were given a total of approximately 1100 infusions. They started at the age of 2 to 8 (mean, 4.5) years and received these infusions for 1.5 to 6 (mean, 3) years. By administering immunoglobulin doses from 58 to 149 (mean, 97) mg/kg per week, trough serum immunoglobulin G values from 5.2 to 9.6 (mean, 7) g/L were obtained. No serious infections occurred. Short-lasting, local side effects such as swelling and redness were frequently reported, but pain or systemic adverse reactions during or after the infusions were never encountered.

Conclusions. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies is a feasible and safe treatment alternative.

Key Words: home therapy • subcutaneous immunoglobulin infusions • children • congenital immunodeficiencies

Submitted on October 4, 1995
Accepted on January 23, 1996




This article has been cited by other articles:


Home page
 Home Health Care Management PracticeHome page
A. R. Zampelli
Improving Quality of Life at Home for Pediatric Patients and Families With Primary Immune Deficiencies Using Subcutaneous Immune Globulin Infusions
Home Health Care Management Practice, October 1, 2007; 19(6): 431 - 435.
[Abstract] [PDF]

Home page
 Arch. Dis. Child.Home page
J Gaspar, B Gerritsen, and A Jones
Immunoglobulin replacement treatment by rapid subcutaneous infusion
Arch. Dis. Child., July 1, 1998; 79(1): 48 - 51.
[Abstract] [Full Text]